Arrigo F.G. Cicero: Bempedoic Acid and Venous Thromboembolism Risk
Arrigo F.G. Cicero, Head of the Clinical Lipidology and Cardiovascular Prevention Laboratory at the University of Bologna, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JAMA Cardiology, adding:
“Pleased to share our newly published Letter in JAMA Cardiology: ‘Venous Thromboembolism Risk and Lipid-Lowering Therapy.’
Prompted by the intriguing 42% relative reduction in venous thromboembolism observed with bempedoic acid in a post hoc analysis of the CLEAR Outcomes trial, we discuss a broader perspective on lipid-lowering therapy.
Perhaps we should communicate these treatments not simply as a way to ‘lower cholesterol,’ but as part of a broader strategy for vascular protection.
This distinction matters – scientifically, clinically, and also in the way we engage with our patients.”
Title: Venous Thromboembolism Risk and Lipid-Lowering Therapy
Authors: Federica Fogacci, Ivan Pecin, Arrigo F. G. Cicero
Stay updated with Hemostasis Today.
-
Oct 13, 2026, 11:24Brandon Daniel D’Costa: Building Stronger Stakeholder Relationships Through Empathy and Open Communication
-
Oct 13, 2026, 11:08Renel Tique: 5th International Conference on Hemophilia and Rare Bleeding Disorders
-
Oct 13, 2026, 02:01Nour Al-Mozain: Is It Really Anti-D? – Unraveling Auto-Anti-LW in the Transfusion Laboratory
-
Oct 13, 2026, 01:51Berenice Villegas: The Role of Morphologic Evaluation in Body Fluid Differential Analysis
-
Oct 13, 2026, 01:44Debadrita Ray: Evaluating vWF and VITRO Score for Detecting CSPH in cACLD Patients
-
Oct 13, 2026, 01:34Nagesh Ramesh: Donating Blood for International Plasma Awareness Week
-
Oct 12, 2026, 21:51Sam Botchey: Orthobiologics Are Advancing but the Evidence Must Keep Pace
-
Oct 12, 2026, 21:50Serum Vitamin D, Platelet Function, and Bleeding in Primary ITP – Platelets Journal
-
Oct 12, 2026, 21:30Nika Samadzadeh Tabrizi: Looking Forward to the PACeS Trial on Anticoagulation for POAF